NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Forecast & News

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.15. The biopharmaceutical company earned $8.04 million during the quarter, compared to analyst estimates of $11.70 million. Dicerna Pharmaceuticals had a negative return on equity of 58.92% and a negative net margin of 541.24%. View Dicerna Pharmaceuticals' Earnings History.

Dicerna Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Dicerna Pharmaceuticals.

8 equities research analysts have issued 1 year price objectives for Dicerna Pharmaceuticals' shares. Their forecasts range from $18.00 to $50.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $31.57 in the next year. This suggests a possible upside of 55.3% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.

News stories about DRNA stock have trended very positive on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 2,670,000 shares, a decline of 14.1% from the December 15th total of 3,110,000 shares. Based on an average daily volume of 887,700 shares, the days-to-cover ratio is currently 3.0 days. Currently, 4.8% of the shares of the stock are sold short. View Dicerna Pharmaceuticals' Current Options Chain.

Some companies that are related to Dicerna Pharmaceuticals include Arrowhead Pharmaceuticals (ARWR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), Allakos (ALLK), Blueprint Medicines (BPMC), Nektar Therapeutics (NKTR), SAGE Therapeutics (SAGE), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH) and Ultragenyx Pharmaceutical (RARE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), Array Biopharma (ARRY), TG Therapeutics (TGTX), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Amarin (AMRN), Arrowhead Pharmaceuticals (ARWR) and Fate Therapeutics (FATE).

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $20.33.

Dicerna Pharmaceuticals has a market capitalization of $1.39 billion and generates $6.18 million in revenue each year. The biopharmaceutical company earns $-88,850,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.View Additional Information About Dicerna Pharmaceuticals.

The official website for Dicerna Pharmaceuticals is http://www.dicerna.com/.

Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]